JPMorgan analyst Chris Schott lowered the firm’s price target on Coherus Biosciences to $11 from $13 and keeps a Neutral rating on the shares post earnings. Cimerli off to a solid start but more than offset by lower Udenyca estimates, Schott tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CHRS:
